SAMSUNG PHARM. Co., LTD. (001360.KS)
KRW 1603.0
(0.25%)
KRW 1603.0
(0.25%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -3.68 Billion KRW | 89.15% |
| 2022 | -33.98 Billion KRW | -41.74% |
| 2021 | -23.97 Billion KRW | -1507.14% |
| 2020 | 1.7 Billion KRW | -77.98% |
| 2019 | 7.73 Billion KRW | -49.46% |
| 2018 | 15.3 Billion KRW | -63.92% |
| 2017 | 42.43 Billion KRW | 9.39% |
| 2016 | 38.79 Billion KRW | -29.56% |
| 2015 | 55.07 Billion KRW | 140.28% |
| 2014 | 22.92 Billion KRW | -39.8% |
| 2013 | 38.07 Billion KRW | -3.59% |
| 2012 | 39.48 Billion KRW | 34.89% |
| 2011 | 29.27 Billion KRW | 11.66% |
| 2010 | 26.21 Billion KRW | 31.87% |
| 2009 | 19.88 Billion KRW | 37.44% |
| 2008 | 14.46 Billion KRW | -10.93% |
| 2007 | 16.24 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -35.08 Billion KRW | -851.9% |
| 2024 Q2 | -17.72 Billion KRW | 49.47% |
| 2023 Q1 | -25.44 Billion KRW | 25.12% |
| 2023 Q4 | -3.68 Billion KRW | -419.08% |
| 2023 Q3 | -710.06 Million KRW | 92.8% |
| 2023 FY | -3.68 Billion KRW | 89.15% |
| 2023 Q2 | -9.86 Billion KRW | 61.24% |
| 2022 Q3 | -57.47 Billion KRW | -95.14% |
| 2022 FY | -33.98 Billion KRW | -41.74% |
| 2022 Q4 | -33.98 Billion KRW | 40.87% |
| 2022 Q1 | -28.1 Billion KRW | -17.22% |
| 2022 Q2 | -29.45 Billion KRW | -4.79% |
| 2021 Q4 | -23.97 Billion KRW | -131.15% |
| 2021 Q3 | -10.37 Billion KRW | 80.52% |
| 2021 Q2 | -53.23 Billion KRW | 4.97% |
| 2021 Q1 | -56.02 Billion KRW | -3387.69% |
| 2021 FY | -23.97 Billion KRW | -1507.14% |
| 2020 Q3 | 5.18 Billion KRW | 405.73% |
| 2020 Q1 | 3.12 Billion KRW | 0.0% |
| 2020 Q2 | -1.69 Billion KRW | -154.33% |
| 2020 Q4 | 1.7 Billion KRW | -67.13% |
| 2020 FY | 1.7 Billion KRW | -77.98% |
| 2019 FY | 7.73 Billion KRW | -49.46% |
| 2019 Q1 | 5.39 Billion KRW | -64.77% |
| 2019 Q2 | 12 Billion KRW | 122.5% |
| 2019 Q3 | 12.22 Billion KRW | 1.89% |
| 2018 Q1 | 33.49 Billion KRW | -21.06% |
| 2018 Q4 | 15.3 Billion KRW | 90.05% |
| 2018 Q2 | 4.94 Billion KRW | -85.25% |
| 2018 FY | 15.3 Billion KRW | -63.92% |
| 2018 Q3 | 8.05 Billion KRW | 62.99% |
| 2017 FY | 42.43 Billion KRW | 9.39% |
| 2017 Q4 | 42.43 Billion KRW | -16.0% |
| 2017 Q3 | 50.51 Billion KRW | 5.05% |
| 2017 Q2 | 48.08 Billion KRW | 16.56% |
| 2017 Q1 | 41.25 Billion KRW | 6.36% |
| 2016 FY | 38.79 Billion KRW | -29.56% |
| 2016 Q4 | 38.79 Billion KRW | 118.49% |
| 2016 Q3 | 17.75 Billion KRW | -60.96% |
| 2016 Q2 | 45.47 Billion KRW | -1.87% |
| 2016 Q1 | 46.34 Billion KRW | -15.85% |
| 2015 Q2 | 31.83 Billion KRW | 0.0% |
| 2015 Q3 | 50.9 Billion KRW | 59.87% |
| 2015 Q4 | 55.07 Billion KRW | 8.2% |
| 2015 FY | 55.07 Billion KRW | 140.28% |
| 2014 FY | 22.92 Billion KRW | -39.8% |
| 2014 Q4 | 22.92 Billion KRW | 0.0% |
| 2014 Q1 | 37.78 Billion KRW | -0.74% |
| 2013 FY | 38.07 Billion KRW | -3.59% |
| 2013 Q4 | 38.07 Billion KRW | 0.61% |
| 2013 Q3 | 37.84 Billion KRW | -0.26% |
| 2013 Q2 | 37.93 Billion KRW | -0.91% |
| 2013 Q1 | 38.28 Billion KRW | -3.05% |
| 2012 Q1 | 34.69 Billion KRW | 18.51% |
| 2012 Q2 | 35.74 Billion KRW | 3.02% |
| 2012 Q3 | 36.25 Billion KRW | 1.45% |
| 2012 Q4 | 39.48 Billion KRW | 8.91% |
| 2012 FY | 39.48 Billion KRW | 34.89% |
| 2011 Q4 | 29.27 Billion KRW | 0.67% |
| 2011 Q2 | 29.14 Billion KRW | 8.22% |
| 2011 Q1 | 26.93 Billion KRW | 2.72% |
| 2011 Q3 | 29.08 Billion KRW | -0.23% |
| 2011 FY | 29.27 Billion KRW | 11.66% |
| 2010 Q2 | 22.85 Billion KRW | 8.62% |
| 2010 Q3 | 24.16 Billion KRW | 5.76% |
| 2010 Q4 | 26.21 Billion KRW | 8.48% |
| 2010 Q1 | 21.03 Billion KRW | 5.81% |
| 2010 FY | 26.21 Billion KRW | 31.87% |
| 2009 Q3 | 16.73 Billion KRW | 13.45% |
| 2009 Q1 | 14.53 Billion KRW | 0.45% |
| 2009 Q4 | 19.88 Billion KRW | 18.82% |
| 2009 Q2 | 14.74 Billion KRW | 1.49% |
| 2009 FY | 19.88 Billion KRW | 37.44% |
| 2008 Q2 | 14.42 Billion KRW | 2.71% |
| 2008 Q3 | 14.42 Billion KRW | -0.03% |
| 2008 Q4 | 14.46 Billion KRW | 0.29% |
| 2008 FY | 14.46 Billion KRW | -10.93% |
| 2008 Q1 | 14.04 Billion KRW | -13.5% |
| 2007 Q3 | 15.71 Billion KRW | -1.54% |
| 2007 FY | 16.24 Billion KRW | 0.0% |
| 2007 Q4 | 16.24 Billion KRW | 3.33% |
| 2007 Q1 | 11.29 Billion KRW | 0.0% |
| 2007 Q2 | 15.96 Billion KRW | 41.28% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 141.874% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 100.644% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 101.186% |
| HANDOK Inc. | 283.45 Billion KRW | 101.3% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | 118.363% |
| Yuhan Corporation | -69.18 Billion KRW | 94.673% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 101.9% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 100.712% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 88.635% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 104.871% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | 110.006% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 104.467% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | 114.68% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 141.874% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 97.694% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 101.834% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 102.156% |
| JW Holdings Corporation | 480.68 Billion KRW | 100.767% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 102.239% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | 3236.024% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 102.388% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 256.755% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | 116.024% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 102.107% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | 107.092% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 141.874% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 102.328% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 101.029% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 102.388% |
| Yuhan Corporation | -69.18 Billion KRW | 94.673% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 102.71% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 106.177% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 100.859% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 102.388% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 103.171% |
| Korea United Pharm Inc. | 16.42 Billion KRW | 122.44% |
| CKD Bio Corp. | 143.29 Billion KRW | 102.572% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 103.176% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 84.682% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 91.761% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 256.755% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 100.872% |
| Boryung Corporation | 187.72 Billion KRW | 101.963% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 94.869% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 104.871% |
| JW Lifescience Corporation | 26.09 Billion KRW | 114.127% |